References - Neonatal Intensive Care Drug Manual

|
Neonatal Intensive Care Drug Manual
|
bet | 531/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
References
|
NICE Guideline 2015. Gastro-oesophageal reflux disease in children and young people: diagnosis and management. Published: 14 January 2015. nice.org.uk/guidance/ng1.
Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition.
Shawyer AC, D'Souza J, Pemberton J, Flageole H. The management of postoperative reflux in congenital esophageal atresia-tracheoesophageal fistula: a systematic review. Pediatr Surg Int 2014;30(10):987-96.
Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD008550. DOI: 10.1002/14651858.CD008550.pub2.
Freedberg DE, Lamouse-Smith ES, Lightdale JR, Jin Z, Yang YX, Abrams JA. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis 2015;61(6):912-7.
Jimenez J, Drees M, Loveridge-Lenza B, Eppes S, del Rosario F. Exposure to Gastric Acid-Suppression Therapy Is Associated With Health Care- and Community-Associated Clostridium difficile Infection in Children. J Pediatr Gastroenterol Nutr 2015;61(2):208-11.
Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol 2015;80(2):200-8.
Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006;117:e137–42.
Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Canani RB. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012;129:e40-5.
Bilali A, Galanis P, Bartsocas C, et al. H2-blocker therapy and incidence of necrotizing enterocolitis in preterm infants: a case-control study. Pediatr Neonatol 2013;54:141–2.
Chandrasekaran M, Fleming P. Question 1: does the use of ranitidine increase the risk of NEC in preterm infants? Arch Dis Child 2014;99(4):390-2.
Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr 2009;155(4):516-21.
Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A, Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117(5):e817-20.
Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001;20:1119–24.
Kuusela, A. L., et al. "A randomized, controlled study of prophylactic ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients." Critical Care Medicine 1997; 25(2): 346-351.
Pourarian, S., et al. "Prophylactic ranitidine in prevention of GI bleeding in neonatal intensive care units." Iranian Journal of Medical Sciences 2005;30(4): 178-181.
van der Pol, R., et al. "Efficacy and safety of histamine-2 receptor antagonists." JAMA Pediatrics 2014;168(10): 947-954.
More, K., et al. "Association of inhibitors of gastric acid secretion and higher incidence of necrotizing enterocolitis in preterm very low-birth-weight infants." American Journal of Perinatology 2013;30(10): 849-856.
Bianconi, S., et al. "Ranitidine and late-onset sepsis in the neonatal intensive care unit." Journal of Perinatal Medicine 2007;35(2): 147-150.
Kuusela AL. Long term gastric pH monitoring for determining optimal dose of ranitidine for critically ill preterm and term neonates. Arch Dis Child Fetal Neonatal Ed 1998;78:F151–F153.
Sutphen JL, Dillard VL. Effect of ranitidine on twenty-four-hour gastric acidity in infants. J pediatr 1989;114:472.
Fontana M, Massironi E, Rossi A, Vaglia P, Gancia GP, Tagliabue P, Principi N. Ranitidine pharmacokinetics in newborn infants. Archives of Disease in Childhood 1993;68(5 Spec No):602-3.
Australian Injectable Drugs Handbook, 6th Edition, Society of Hospital Pharmacists of Australia 2014.
Micromedex® 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.acs.hcn.com.au/ (cited: 07/2016).
MIMS online available via CIAP (cited: 07/2016).
|
|
| |